XUANZHUBIO-B

2575
8.4452.18% ( +0.180 )
Delay Closed: Nov 16, 16:08:11

Overview

XUANZHUBIO-B (2575)

Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular bio...

Open
8.605
High
8.840
Low
8.190
Prev. Close
8.265
Volume
2.12M
Turnover
18.11M
Avg Price
8.532
Bid/Ask Ratio
25.00%
Amplitude
7.86%
52wk High
96.900
Volume Ratio
5.07
Turnover Ratio
0.41%
52wk Low
7.520
HK Mkt Cap
4.37B
Market CapHKD
4.37B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.467
EPSDynamic
-0.335
EPSStatic
--
BVPS
2.88
P/B
2.93
HK Shares
517.95M
Dividend YieldTTM
--
DividendTTM
--
Shares
517.95M
Min lot size
500
Currency
HKD

Daily Events

  1. Nov, 16

    Xuanzhu Biopharmaceutical-B rebounded off an early dip but gave back gains late, closing at HK$8.440, up 2.12%, after touching HK$8.190 at 10:17 in the morning session and spiking to HK$8.825 at 13:51 in the afternoon without holding, on HK$18.06m of turnover. Sentiment was supported by the inclusion of a new bireociclib indication in China's 2026 NRDL, alongside the earlier Phase III success of anaprazole sodium in reflux esophagitis. Operations improved: Q2 2026 revenue of HK$40.1m rose 309% year on year while net loss narrowed 28.4% to HK$43.5m, though net margin stayed at -108.5%. The price position remains weak: down 87.06% year to date, 91.29% below the HK$96.9 52-week high and just 12.23% above the HK$7.52 low set on 1 November, with the stock above its MA20 of HK$8.396 but below MA60 of HK$8.908. Though at a HK$4.37bn market cap, turnover of just 0.41% suggests the near-8% intraday range reflects small-cap idiosyncratic swings.

  2. Nov, 13

    Xuanzhu Bio (2575.HK) spiked then faded, touching HK$9.010 in the morning session as residual buying followed the Phase III anaprazole sodium trial in reflux esophagitis meeting its primary endpoint, before sliding through the afternoon to HK$8.240 and closing at HK$8.270, down 6.97% from the prior close of HK$8.890 on 1.679 million shares worth HK$14.38 million. Operating revenue for Q2 2026 reached HK$40.10 million, up 309.08% year on year, and the net loss narrowed 28.4% to HK$43.51 million with EPS improving to -HK$0.084, yet the net margin stayed at -108.49%, so the fundamental repair did not hold the price. The stock is 87.32% lower year to date, 91.47% below its 52-week high of HK$96.90 and only 9.97% above the November 1 low of HK$7.52, and the close sits under both the MA20 of HK$8.383 and MA60 of HK$8.951. Though the shares rebounded 8.28% off a record low in the prior week, intraday action still reflects name-by-name flows in small-cap biotech.

  3. Nov, 12

    Xuanzhu Bio-B opened lower, probed the low and then rallied on heavy volume to close at HK$8.885, up 6.41%, driven by continued digestion of the news that anaprazole sodium met the primary endpoint in its Phase III reflux esophagitis trial, layered on an oversold rebound after the stock touched its 52-week low of HK$7.52 on 2 November. The morning session dipped to HK$8.210, while the afternoon saw 2.805 million shares trade as the price pushed to HK$8.925, with full-day volume of 3.1855 million shares. Q2 2026 revenue was HK$40.10 million, up 309.08% year on year, and the net loss narrowed 28.4% to HK$43.51 million, though the net margin remained -108.49% and ROE -11.64%. The price sits above the 20-day MA of HK$8.39 but below the 60-day MA of HK$9.00, down 86.37% year to date and 90.83% below the 52-week high of HK$96.9, with a PB of 3.09 times. The company is still loss-making on a low revenue base, so whether the rebound extends depends on commercial execution.

  4. Nov, 5

    Xuanzhu Bio-B opened at the day's low of HK$8.470, climbed steadily, spiked to HK$8.940 at 13:03 BJ, then faded to close at HK$8.655, up 4.15% on 2.09 million shares, a spike-and-fade pattern. The driver remains the afterglow of anaprazole sodium meeting the primary endpoint in a Phase III reflux esophagitis trial and the data being presented at UEG Week 2026, a catalyst that earlier lifted the stock more than 18% in one session and also preceded a 7% drop to a record low of HK$7.52 on 2 November, so headlines keep amplifying the swings. Fundamentals are improving alongside: Q2 2026 revenue reached HK$40.1 million, up 309.08% year on year, while the net loss narrowed 28.4% to HK$43.5 million and the net margin stayed at -108.49%. The price sits above MA20 of HK$8.359 but below MA60 of HK$9.338, down 86.73% year to date and 91.07% below the 52-week high of HK$96.9, with a market value of HK$4.48 billion. Still, turnover of just 0.400% points to thin participation.

  5. Nov, 3

    Xuanzhu Bio-B (2575.HK) closed up 4.85% at HK$8.105 after UEG Week 2026 featured Phase III data for anaprazole sodium in reflux esophagitis, driving an intraday spike to HK$9.245 — nearly 20% above the prior close of HK$7.730 — before most of the gain was surrendered and the stock chopped between HK$8.615 and HK$7.935 in the afternoon on 7.55 million shares worth HK$64.8 million. The bounce followed a session in which it printed a record low of HK$7.52; the shares remain down 87.57% year-to-date and sit below both the MA20 (HK$8.363) and MA60 (HK$9.484). Fundamentals are still loss-making but improving: Q2 2026 revenue of HK$40.1 million rose 309% year-on-year while the net loss of HK$43.5 million narrowed 28.4%, leaving EPS at -HK$0.084, net margin at -108.5%, PB at 2.82x and market capitalisation near HK$4.2 billion. Though a single data readout leaves the stock 91.64% below its 52-week high, with the turnover rate at just 1.46%.

News